Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways.

ABSTRACT: Cisplatin is currently used to treat inoperable recurrent meningiomas, but its side effects and drug resistance limit its use. Metformin has recently been identified as a chemosensitizing agent. However, the combined treatment of cisplatin and metformin in high-grade meningiomas has not been reported. Herein, our findings demonstrate metformin significantly enhanced cisplatin-induced inhibition of proliferation in meningioma cells, which was associated with the induction of G0/G1 cell cycle arrest. Additionally, metformin activated adenosine monophosphate activated protein kinase (AMPK) and repressed the mammalian target of rapamycin (mTOR) signaling pathways via an AMPK-dependent mechanism. Furthermore, our xenograft murine model confirmed that metformin enhanced cisplatin's anti-cancer e

SUBMITTER: Guo L 

PROVIDER: S-EPMC7851485 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature